3 news items
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
DRMA
15 May 24
. The increase in research and development expense was the result of increased clinical trial expenses from the Company's STAR-1 clinical study as well
Dermata Therapeutics FY23 EPS $(2.67) Vs $(13.92) YoY
DRMA
21 Mar 24
. The Company expects its current cash resources to be sufficient to fund operations into the third quarter of 2024.Research and development expenses
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
DRMA
21 Mar 24
current cash resources to be sufficient to fund operations into the third quarter of 2024.Research and development expenses were $4.1 million
- Prev
- 1
- Next